Systematic review of 131 studies (some meta-analysed) in difficult-to-treat RA: all b/tsDMARDs except otilimab beat placebo after ≥2 prior b/tsDMARDs (mostly high risk of bias); JAK inhibitor efficacy held despite more prior failures, with more infection and malignancy.
Meta-analysisn = 131 studies
Shams et al. Therapeutic approaches for difficult-to-treat rheumatoid arthritis: a systematic literature review of current evidence